Candel Therapeutics files new $50 million at-the-market stock sale agreement with Jefferies
Candel updated its sales arrangement with Jefferies on November 12, 2026, after fully using up its prior $50 million agreement.
SEC filing
3 stories
Candel updated its sales arrangement with Jefferies on November 12, 2026, after fully using up its prior $50 million agreement.
SEC filing
Eikon Therapeutics disclosed updated lung cancer data, a registrational trial start, and an IND filing for a new prostate cancer drug, alongside $461.7 million in cash.
SEC filing (12)
The regulatory and quality veteran joins as Candel prepares a fourth-quarter 2026 BLA submission for aglatimagene besadenovec.
SEC filing